AC6.F

Healthcare Biotechnology

AlzeCure Pharma AB (publ)

€0.56

-0.01 -2.43% today

Price History

Not enough data

Key Stats

Market Cap

64.58M

Avg Volume

464

P/E (TTM)

18.73

EPS

€0.03

52W High

€0.74

52W Low

€0.07

Div. Yield

0.0%

Valuation

P/B Ratio

1.27

Margins

Gross Margin 100.0%

Operating Margin 0.0%

Net Margin 31.6%

EBITDA Margin 32.3%

Growth & Returns

Return on Equity

62.9%

Return on Assets

27.3%

Liquidity & Leverage

Current Ratio

4.11

Quick Ratio

0.70

Debt / Equity

0.02

About

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857 and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist, which is in phase II clinical trial for neuropathic pain indications; and ACD137 negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications, which is in preclinical phase. AlzeCure Pharma AB (publ) was founded in 2012 and is based in Huddinge, Sweden.